CEL Price To Sales Ratio vs Free Cash Flow Yield Analysis

CVM Stock

USD 0.69 0.05 6.76%

CEL SCI financial indicator trend analysis is way more than just evaluating CEL SCI Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CEL SCI Corp is a good investment. Please check the relationship between CEL SCI Price To Sales Ratio and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CEL SCI Corp Price To Sales Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have no relationship.

The correlation between CEL SCI's Price To Sales Ratio and Free Cash Flow Yield is 0.0. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of CEL SCI Corp, assuming nothing else is changed. The correlation between historical values of CEL SCI's Price To Sales Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of CEL SCI Corp are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Price To Sales Ratio i.e., CEL SCI's Price To Sales Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing CEL SCI Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CEL SCI sales, a figure that is much harder to manipulate than other CEL SCI Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from CEL SCI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CEL SCI Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

As of the 16th of December 2024, Enterprise Value is likely to grow to about 82.9 M, while Selling General Administrative is likely to drop about 5.2 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	36.1M	31.5M	36.2M	38.0M
Cost Of Revenue	3.9M	4.0M	3.6M	3.1M

Total Operating Expenses Cost Of Revenue

CEL SCI fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt	Intangible Assets	Accounts Payable	Net Receivables	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.03	0.16	0.89	0.85	-0.48	-0.76	0.91	0.87	0.91	0.75	-0.18	0.74	0.52	0.75	0.91	-0.43	0.6	0.64	0.59	-0.32	-0.07	-0.45	-0.25	0.45	-0.27
Other Current Liab	0.03		0.42	-0.24	0.28	0.48	-0.23	-0.22	0.31	-0.2	0.22	-0.4	0.31	0.48	0.38	-0.21	-0.07	0.41	0.24	-0.29	-0.2	0.3	-0.17	0.0	-0.15	-0.04
Total Current Liabilities	0.16	0.42		-0.2	0.32	0.33	-0.4	-0.02	0.32	-0.03	0.09	-0.11	0.31	0.77	0.28	-0.03	-0.19	0.59	0.57	0.27	-0.58	0.92	-0.17	-0.32	-0.29	-0.32
Total Stockholder Equity	0.89	-0.24	-0.2		0.62	-0.68	-0.5	0.9	0.64	0.91	0.57	-0.05	0.49	0.08	0.56	0.92	-0.29	0.19	0.28	0.53	-0.15	-0.39	-0.32	-0.17	0.63	-0.17
Property Plant And Equipment Net	0.85	0.28	0.32	0.62		-0.01	-0.83	0.61	0.98	0.6	0.92	-0.54	0.86	0.66	0.92	0.58	-0.67	0.69	0.76	0.62	-0.57	0.05	-0.65	-0.44	0.19	-0.48
Net Debt	-0.48	0.48	0.33	-0.68	-0.01		-0.07	-0.74	-0.03	-0.75	0.06	-0.3	0.11	0.19	0.06	-0.76	-0.07	0.07	0.18	-0.18	-0.37	0.34	-0.21	-0.05	-0.63	-0.08
Retained Earnings	-0.76	-0.23	-0.4	-0.5	-0.83	-0.07		-0.5	-0.89	-0.47	-0.85	0.2	-0.95	-0.69	-0.8	-0.5	0.3	-0.7	-0.81	-0.68	0.59	-0.1	0.79	0.19	0.13	0.21
Cash	0.91	-0.22	-0.02	0.9	0.61	-0.74	-0.5		0.61	1.0	0.49	-0.03	0.45	0.33	0.48	0.99	-0.37	0.45	0.44	0.45	-0.09	-0.15	-0.16	-0.18	0.59	-0.18
Non Current Assets Total	0.87	0.31	0.32	0.64	0.98	-0.03	-0.89	0.61		0.6	0.92	-0.4	0.92	0.65	0.92	0.6	-0.5	0.68	0.75	0.63	-0.52	0.03	-0.7	-0.33	0.13	-0.37
Cash And Short Term Investments	0.91	-0.2	-0.03	0.91	0.6	-0.75	-0.47	1.0	0.6		0.47	-0.03	0.43	0.31	0.48	1.0	-0.35	0.42	0.42	0.41	-0.08	-0.15	-0.13	-0.18	0.65	-0.17
Common Stock Shares Outstanding	0.75	0.22	0.09	0.57	0.92	0.06	-0.85	0.49	0.92	0.47		-0.52	0.92	0.5	0.9	0.47	-0.54	0.56	0.71	0.64	-0.53	-0.21	-0.8	-0.3	0.07	-0.35
Other Current Assets	-0.18	-0.4	-0.11	-0.05	-0.54	-0.3	0.2	-0.03	-0.4	-0.03	-0.52		-0.28	-0.26	-0.59	0.03	0.8	-0.26	-0.32	-0.14	0.53	0.02	0.33	0.66	-0.19	0.69
Other Stockholder Equity	0.74	0.31	0.31	0.49	0.86	0.11	-0.95	0.45	0.92	0.43	0.92	-0.28		0.62	0.87	0.45	-0.29	0.62	0.78	0.65	-0.57	0.0	-0.84	-0.16	-0.1	-0.21
Total Liab	0.52	0.48	0.77	0.08	0.66	0.19	-0.69	0.33	0.65	0.31	0.5	-0.26	0.62		0.54	0.3	-0.42	0.96	0.86	0.29	-0.45	0.63	-0.31	-0.26	-0.19	-0.28
Property Plant And Equipment Gross	0.75	0.38	0.28	0.56	0.92	0.06	-0.8	0.48	0.92	0.48	0.9	-0.59	0.87	0.54		0.48	-0.56	0.54	0.7	0.57	-0.66	-0.01	-0.78	-0.34	0.18	-0.39
Total Current Assets	0.91	-0.21	-0.03	0.92	0.58	-0.76	-0.5	0.99	0.6	1.0	0.47	0.03	0.45	0.3	0.48		-0.29	0.41	0.42	0.43	-0.08	-0.16	-0.16	-0.13	0.63	-0.12
Non Currrent Assets Other	-0.43	-0.07	-0.19	-0.29	-0.67	-0.07	0.3	-0.37	-0.5	-0.35	-0.54	0.8	-0.29	-0.42	-0.56	-0.29		-0.47	-0.51	-0.32	0.53	-0.1	0.22	0.65	-0.3	0.66
Non Current Liabilities Total	0.6	0.41	0.59	0.19	0.69	0.07	-0.7	0.45	0.68	0.42	0.56	-0.26	0.62	0.96	0.54	0.41	-0.47		0.85	0.27	-0.34	0.45	-0.28	-0.22	-0.1	-0.24
Short Long Term Debt Total	0.64	0.24	0.57	0.28	0.76	0.18	-0.81	0.44	0.75	0.42	0.71	-0.32	0.78	0.86	0.7	0.42	-0.51	0.85		0.46	-0.64	0.42	-0.5	-0.27	-0.02	-0.3
Short Term Debt	0.59	-0.29	0.27	0.53	0.62	-0.18	-0.68	0.45	0.63	0.41	0.64	-0.14	0.65	0.29	0.57	0.43	-0.32	0.27	0.46		-0.59	-0.02	-0.74	-0.35	-0.12	-0.35
Intangible Assets	-0.32	-0.2	-0.58	-0.15	-0.57	-0.37	0.59	-0.09	-0.52	-0.08	-0.53	0.53	-0.57	-0.45	-0.66	-0.08	0.53	-0.34	-0.64	-0.59		-0.37	0.62	0.5	0.06	0.5
Accounts Payable	-0.07	0.3	0.92	-0.39	0.05	0.34	-0.1	-0.15	0.03	-0.15	-0.21	0.02	0.0	0.63	-0.01	-0.16	-0.1	0.45	0.42	-0.02	-0.37		0.15	-0.25	-0.24	-0.23
Net Receivables	-0.45	-0.17	-0.17	-0.32	-0.65	-0.21	0.79	-0.16	-0.7	-0.13	-0.8	0.33	-0.84	-0.31	-0.78	-0.16	0.22	-0.28	-0.5	-0.74	0.62	0.15		0.1	0.3	0.14
Common Stock Total Equity	-0.25	0.0	-0.32	-0.17	-0.44	-0.05	0.19	-0.18	-0.33	-0.18	-0.3	0.66	-0.16	-0.26	-0.34	-0.13	0.65	-0.22	-0.27	-0.35	0.5	-0.25	0.1		-0.19	0.99
Short Term Investments	0.45	-0.15	-0.29	0.63	0.19	-0.63	0.13	0.59	0.13	0.65	0.07	-0.19	-0.1	-0.19	0.18	0.63	-0.3	-0.1	-0.02	-0.12	0.06	-0.24	0.3	-0.19		-0.18
Common Stock	-0.27	-0.04	-0.32	-0.17	-0.48	-0.08	0.21	-0.18	-0.37	-0.17	-0.35	0.69	-0.21	-0.28	-0.39	-0.12	0.66	-0.24	-0.3	-0.35	0.5	-0.23	0.14	0.99	-0.18

Click cells to compare fundamentals

CEL SCI Account Relationship Matchups

CEL SCI fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	40.5M	75.9M	50.5M	30.5M	35.1M	36.9M
Other Current Liab	102.2K	863.9K	(417.5K)	1.6M	1.8M	1.8M
Total Current Liabilities	4.3M	3.9M	4.7M	5.6M	6.4M	3.6M
Total Stockholder Equity	19.7M	56.5M	32.2M	13.2M	15.2M	8.4M
Property Plant And Equipment Net	20.9M	28.4M	24.7M	21.0M	24.2M	25.4M
Net Debt	(1.6M)	(20.1M)	(7.4M)	9.4M	8.5M	8.9M
Retained Earnings	(381.8M)	(418.2M)	(454.9M)	(487.1M)	(438.4M)	(416.5M)
Cash	15.5M	36.1M	22.7M	4.1M	4.8M	7.7M
Non Current Assets Total	22.8M	30.6M	25.1M	23.6M	27.2M	28.5M
Cash And Short Term Investments	15.5M	42.2M	22.7M	4.1M	4.8M	8.1M
Common Stock Shares Outstanding	36.8M	40.7M	43.1M	44.5M	51.2M	53.7M
Liabilities And Stockholders Equity	40.5M	75.9M	50.5M	30.5M	35.1M	36.9M
Other Current Assets	1.3M	998.5K	762.1K	524.6K	472.2K	448.5K
Other Stockholder Equity	401.2M	474.3M	486.6M	499.8M	574.8M	603.5M
Total Liab	20.8M	19.3M	18.4M	17.3M	19.9M	20.9M
Property Plant And Equipment Gross	5.8M	32.5M	30.6M	29.0M	33.3M	35.0M
Total Current Assets	17.7M	45.3M	25.4M	6.9M	8.0M	9.9M
Non Current Liabilities Total	16.5M	15.4M	13.7M	11.7M	13.5M	14.2M
Short Long Term Debt Total	13.9M	16.0M	15.3M	13.6M	15.6M	16.4M
Short Term Debt	2.1M	1.4M	3.5M	2.0M	2.3M	1.2M
Intangible Assets	313.4K	275.9K	212.2K	197.7K	177.9K	284.1K
Accounts Payable	2.0M	1.7M	1.6M	2.0M	2.3M	1.4M
Net Receivables	118.7K	62.8K	54.9K	(2.0M)	(1.8M)	(1.7M)
Common Stock Total Equity	352.3K	387.3K	432.1K	434.5K	499.7K	959.4K
Common Stock	387.3K	432.1K	434.5K	474.2K	426.8K	682.4K
Other Liab	7.0M	6.0M	3.7M	125K	143.8K	136.6K
Property Plant Equipment	15.8M	5.8M	13.7M	12.1M	13.9M	14.6M
Inventory	820.1K	2.0M	2.0M	2.2M	2.6M	2.7M
Net Tangible Assets	5.1M	19.4M	56.3M	32.0M	36.7M	38.6M
Retained Earnings Total Equity	(353.7M)	(381.8M)	(418.2M)	(454.9M)	(409.4M)	(429.9M)
Capital Surpluse	358.5M	401.2M	474.3M	486.6M	559.6M	351.9M
Non Current Liabilities Other	13.5M	13.0M	125K	13.7M	143.8K	136.6K
Long Term Debt Total	13.5M	11.8M	13.3M	11.7M	13.5M	12.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether CEL SCI Corp is a strong investment it is important to analyze CEL SCI's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CEL SCI's future performance. For an informed investment choice regarding CEL Stock, refer to the following important reports:

How To Invest In CEL

Details

Is CEL Stock a good investment?

Details

What is CEL SCI's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.52)

Revenue Per Share

0.001

Quarterly Revenue Growth

(0.63)

Return On Assets

(0.61)

Return On Equity

(2.50)

The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CEL Price To Sales Ratio vs Free Cash Flow Yield Analysis

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Yield

CEL SCI fundamental ratios Correlations

CEL SCI Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CEL SCI fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Cash
Common Stock	+ 0.99	Common Stock Total Equity
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Non Current Liabilities Total	+ 0.96	Total Liab

Other Stockholder Equity	- 0.95	Retained Earnings
Non Current Assets Total	- 0.89	Retained Earnings
Common Stock Shares Outstanding	- 0.85	Retained Earnings
Net Receivables	- 0.84	Other Stockholder Equity
Retained Earnings	- 0.83	Property Plant And Equipment Net
Short Long Term Debt Total	- 0.81	Retained Earnings